Botulinum Toxin A in bruxers. One year experience

Area of Science:

• Neurology
• Dentistry
• Pharmacology

Background:

• Bruxism, characterized by involuntary jaw clenching and teeth grinding, can lead to significant dental issues and jaw pain.
• Botulinum Toxin A (BTxA) is increasingly explored for its muscle-relaxant properties in treating hyperactive muscles.

Purpose of the Study:

• To evaluate the efficacy, outcomes, and safety profile of Botulinum Toxin A injections for managing bruxism.
• To assess patient satisfaction and identify any adverse events associated with BTxA treatment for bruxism.

Main Methods:

• A cohort of 120 patients diagnosed with bruxism received standardized Botulinum Toxin A injections into the masseter muscles.
• Follow-up assessments included a 15-day post-injection evaluation and a patient satisfaction questionnaire.
• Dosage adjustments and re-injections were administered for patients with suboptimal initial responses.

Main Results:

• Overwhelming patient satisfaction was reported, with all participants noting good to very good symptom improvement.
• A significant majority of patients experienced positive outcomes: 30% fair, 65.8% good, and 4.2% excellent results.
• No significant adverse side effects were documented during the study period.

Conclusions:

• Botulinum Toxin A presents a straightforward and well-tolerated treatment option for bruxism.
• The treatment is highly appreciated by patients due to its effectiveness and lack of side effects.
• Long-term effects of BTxA on masticatory muscles and dental structures warrant further investigation.